Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 181

1.

A 12-month study of the efficacy of rivastigmine in patients with advanced moderate Alzheimer's disease.

Karaman Y, Erdoğan F, Köseoğlu E, Turan T, Ersoy AO.

Dement Geriatr Cogn Disord. 2005;19(1):51-6. Epub 2004 Sep 21.

2.

Galantamine provides sustained benefits in patients with 'advanced moderate' Alzheimer's disease for at least 12 months.

Blesa R, Davidson M, Kurz A, Reichman W, van Baelen B, Schwalen S.

Dement Geriatr Cogn Disord. 2003;15(2):79-87.

PMID:
12566596
3.

Rivastigmine transdermal patch and capsule in Alzheimer's disease: influence of disease stage on response to therapy.

Farlow MR, Grossberg GT, Meng X, Olin J, Somogyi M.

Int J Geriatr Psychiatry. 2011 Dec;26(12):1236-43. doi: 10.1002/gps.2669. Epub 2010 Dec 23.

PMID:
22068922
4.

Analysis of outcome in retrieved dropout patients in a rivastigmine vs placebo, 26-week, Alzheimer disease trial.

Farlow M, Potkin S, Koumaras B, Veach J, Mirski D.

Arch Neurol. 2003 Jun;60(6):843-8.

PMID:
12810489
6.

Donepezil and rivastigmine in the treatment of Alzheimer's disease: a best-evidence synthesis of the published data on their efficacy and cost-effectiveness.

Wolfson C, Oremus M, Shukla V, Momoli F, Demers L, Perrault A, Moride Y.

Clin Ther. 2002 Jun;24(6):862-86; discussion 837. Review.

PMID:
12117079
7.

Effects of donepezil, galantamine and rivastigmine in 938 Italian patients with Alzheimer's disease: a prospective, observational study.

Santoro A, Siviero P, Minicuci N, Bellavista E, Mishto M, Olivieri F, Marchegiani F, Chiamenti AM, Benussi L, Ghidoni R, Nacmias B, Bagnoli S, Ginestroni A, Scarpino O, Feraco E, Gianni W, Cruciani G, Paganelli R, Di Iorio A, Scognamiglio M, Grimaldi LM, Gabelli C, Sorbi S, Binetti G, Crepaldi G, Franceschi C.

CNS Drugs. 2010 Feb;24(2):163-76. doi: 10.2165/11310960-000000000-00000.

PMID:
20088621
8.

Efficacy of rivastigmine in subjects with moderately severe Alzheimer's disease.

Burns A, Spiegel R, Quarg P.

Int J Geriatr Psychiatry. 2004 Mar;19(3):243-9.

PMID:
15027039
9.

Response of patients with Alzheimer disease to rivastigmine treatment is predicted by the rate of disease progression.

Farlow MR, Hake A, Messina J, Hartman R, Veach J, Anand R.

Arch Neurol. 2001 Mar;58(3):417-22.

PMID:
11255445
10.

Rivastigmine for dementia associated with Parkinson's disease.

Emre M, Aarsland D, Albanese A, Byrne EJ, Deuschl G, De Deyn PP, Durif F, Kulisevsky J, van Laar T, Lees A, Poewe W, Robillard A, Rosa MM, Wolters E, Quarg P, Tekin S, Lane R.

N Engl J Med. 2004 Dec 9;351(24):2509-18.

11.
12.

Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomised controlled trial.

Rösler M, Anand R, Cicin-Sain A, Gauthier S, Agid Y, Dal-Bianco P, Stähelin HB, Hartman R, Gharabawi M.

BMJ. 1999 Mar 6;318(7184):633-8. Erratum in: BMJ 2001 Jun 16;322(7300):1456.

14.
15.

Disease stage in Alzheimer disease and treatment effects of rivastigmine.

Kurz A, Farlow M, Quarg P, Spiegel R.

Alzheimer Dis Assoc Disord. 2004 Jul-Sep;18(3):123-8.

PMID:
15494617
16.

Effects of rivastigmine in Alzheimer's disease patients with and without hallucinations.

Cummings J, Emre M, Aarsland D, Tekin S, Dronamraju N, Lane R.

J Alzheimers Dis. 2010;20(1):301-11. doi: 10.3233/JAD-2010-1362.

PMID:
20164585
17.

Rivastigmine in Alzheimer's disease and Parkinson's disease dementia: an ADAS-cog factor analysis.

Weintraub D, Somogyi M, Meng X.

Am J Alzheimers Dis Other Demen. 2011 Sep;26(6):443-9. doi: 10.1177/1533317511424892. Epub 2011 Oct 18.

PMID:
22009228
18.

Efficacy of rivastigmine in Alzheimer's disease patients with rapid disease progression: results of a meta-analysis.

Farlow MR, Small GW, Quarg P, Krause A.

Dement Geriatr Cogn Disord. 2005;20(2-3):192-7. Epub 2005 Aug 3.

19.

Effects of oral rivastigmine on cognitive domains in mild-to-moderate Alzheimer's disease.

Farlow MR, Cummings JL, Olin JT, Meng X.

Am J Alzheimers Dis Other Demen. 2010 Jun;25(4):347-52. doi: 10.1177/1533317510365344. Epub 2010 Apr 14.

PMID:
20392862
20.

Rivastigmine for Alzheimer's disease.

Birks J, Grimley Evans J, Iakovidou V, Tsolaki M.

Cochrane Database Syst Rev. 2000;(4):CD001191. Review. Update in: Cochrane Database Syst Rev. 2009;(2):CD001191.

PMID:
11034705
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk